High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial

2021 ◽  
Vol 22 (3) ◽  
pp. 321-331 ◽  
Author(s):  
Bjørn Henning Grønberg ◽  
Kristin Toftaker Killingberg ◽  
Øystein Fløtten ◽  
Odd Terje Brustugun ◽  
Kjersti Hornslien ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Standard Dose ◽  
Small Cell ◽  
High Dose ◽  
Phase 2 ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

2020 ◽  
Vol 21 (6) ◽  
pp. 786-795 ◽  
Author(s):  
Catherine A Shu ◽  
Justin F Gainor ◽  
Mark M Awad ◽  
Codruta Chiuzan ◽  
Claud M Grigg ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial

scholarly journals Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

Cancer ◽  
2015 ◽  
Vol 121 (18) ◽  
pp. 3298-3306 ◽  
Author(s):  
Karen L. Reckamp ◽  
Marianna Koczywas ◽  
Mihaela C. Cristea ◽  
Jonathan E. Dowell ◽  
He-Jing Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
High Dose ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Phase 2 Trial ◽  
Randomized Phase 2

scholarly journals Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

2016 ◽  
Vol 17 (7) ◽  
pp. 984-993 ◽  
Author(s):  
David Planchard ◽  
Benjamin Besse ◽  
Harry J M Groen ◽  
Pierre-Jean Souquet ◽  
Elisabeth Quoix ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Multicentre Phase ◽  
Phase 2 Trial ◽  
Previously Treated

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

2020 ◽  
Vol 21 (11) ◽  
pp. 1413-1422 ◽  
Author(s):  
Mariano Provencio ◽  
Ernest Nadal ◽  
Amelia Insa ◽  
María Rosario García-Campelo ◽  
Joaquín Casal-Rubio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial
Sign in / Sign up

Export Citation Format

Share Document